Steroids for irAEs and ICI efficacy: analysis from 6 trials
Jarushka Naidoo shared a post on X about a recent paper by Karijn Suijkerbuijk et al. titled “Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials” published in Journal of Clinical Oncology.
Authors: Rik J. Verheijden, Jolien S. de Groot, Babs O. Fabriek, Miki N. Hew, Anne M. May, Karijn P.M. Suijkerbuijk
“Steroids for irAEs and ICI efficacy: patient-level analysis from 6 trials Journal of Clinical Oncology:
- 1959pts (CM-067, -142, -214,-648, -743,)
- 834 had immunosuppression for irAEs
- higher peak steroid dose associated with lower PFS, lower OS, cumulative dose was not.”
Source: Jarushka Naidoo/X
Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland.
She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.
She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.